0% allocated.
MSB is at the very end of highly speculative life science R&D companies. In my opinion, more so than any other agent, device or indicated target.
I am happy with 10-20% allocation to speculative biotech - where more is known about the science, big pharma interest, and public and private buyer behaviour is not a guess.
My investment in MSB was a good learning experience for me.
Risk management, page-3
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.40 |
Change
0.045(3.33%) |
Mkt cap ! $1.592B | |||
| Open | High | Low | Value | Volume |
| $1.35 | $1.42 | $1.33 | $3.802M | 2.753M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 23940 | $1.39 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.40 | 22571 | 2 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |